gabexate has been researched along with Fibrous Dysplasia, Polyostotic in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Fibrous Dysplasia, Polyostotic: FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, A | 1 |
| Tsukawaki, Y | 1 |
| Nioka, S | 1 |
| Yoda, K | 1 |
| Miyazaki, M | 1 |
| Kusaka, Y | 1 |
| Ban, S | 1 |
1 other study available for gabexate and Fibrous Dysplasia, Polyostotic
| Article | Year |
|---|---|
[Pre- and post-operative management of Kasabach-Merritt syndrome].
Topics: Blood Coagulation; Disseminated Intravascular Coagulation; Fibrous Dysplasia of Bone; Fibrous Dyspla | 1984 |